Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
COSMOS PharmaceuticalCSMYF 87 Cash-to-Debt is 0.61 as of Feb. 2026, which is 58% below its 10-year median of 1.45. GuruFocus rates CSMYF with a GF Score™ of 87/100 and a GF Value™ of $48.62. The stock has 2 warning signs investors should review. Among 669 Healthcare Providers & Services companies, COSMOS Pharmaceutical ranks worse than 50.37% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. COSMOS Pharmaceutical's cash to debt ratio for the quarter that ended in Feb. 2026 was 0.61.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, COSMOS Pharmaceuticalcouldn't pay off its debt using the cash in hand for the quarter that ended in Feb. 2026.
The historical rank and industry rank for COSMOS Pharmaceutical's Cash-to-Debt or its related term are showing as below:
CSMYF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.78 Med: 1.45 Max: 5.28
Current: 0.78
During the past 13 years, COSMOS Pharmaceutical's highest Cash to Debt Ratio was 5.28. The lowest was 0.78. And the median was 1.45.
CSMYF's Cash-to-Debt is ranked worse than 50.37% of 669
companies
in the Healthcare Providers & Services industry
Industry Median: 0.79
vs CSMYF: 0.78
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
COSMOS Pharmaceutical Cash-to-Debt Related Terms
COSMOS Pharmaceutical Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for COSMOS Pharmaceutical's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Pharmaceutical Retailers subindustry, COSMOS Pharmaceutical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
COSMOS Pharmaceutical Cash-to-Debt vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, COSMOS Pharmaceutical's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where COSMOS Pharmaceutical's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
COSMOS Pharmaceutical (CSMYF) has a Cash-to-Debt of 0.61 as of Feb. 2026. This is 58% below median its historical median of 1.45. Over the past decade, COSMOS Pharmaceutical's Cash-to-Debt has ranged from 0.78 to 5.28. According to the industry distribution chart, COSMOS Pharmaceutical ranks #337 out of 669 companies in the Healthcare Providers & Services industry, placing it in the top 50.4%.
Is COSMOS Pharmaceutical's Cash-to-Debt too high?
COSMOS Pharmaceutical's current Cash-to-Debt of 0.61 is 58% below median its 10-year median of 1.45. Over the past 10 years, this metric has ranged from a low of 0.78 to a high of 5.28. The Healthcare Providers & Services industry median Cash-to-Debt is 0.79. COSMOS Pharmaceutical's value of 0.61 is 22.8% below this industry median. Based on the distribution chart, COSMOS Pharmaceutical ranks #337 out of 669 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, COSMOS Pharmaceutical has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does COSMOS Pharmaceutical's Cash-to-Debt compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, COSMOS Pharmaceutical ranks #337 out of 669 companies for Cash-to-Debt. This places COSMOS Pharmaceutical in the lower half of its industry. The industry median Cash-to-Debt is 0.79. COSMOS Pharmaceutical's value of 0.61 is 22.8% below this benchmark. Historically, COSMOS Pharmaceutical's own Cash-to-Debt has ranged from 0.78 to 5.28 over the past decade. While the company's 10-year median is 1.45 vs. the industry median of 0.79, COSMOS Pharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.79, based on 669 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. COSMOS Pharmaceutical's current Cash-to-Debt of 0.61 is 22.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. COSMOS Pharmaceutical's current Cash-to-Debt is 0.61, which is 58% below median its own 10-year median of 1.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is COSMOS Pharmaceutical stock overvalued right now?
COSMOS Pharmaceutical (CSMYF) has a current Cash-to-Debt of 0.61. The stock's GF Value™ is $48.62, compared to a current price of $37.06 — trading 23.8% below its estimated fair value. The current Cash-to-Debt is 0.61, which is 58% below median its 10-year median of 1.45 and 22.8% below the Healthcare Providers & Services industry median of 0.79. COSMOS Pharmaceutical's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For COSMOS Pharmaceutical (CSMYF), the current Cash-to-Debt is 0.61 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is COSMOS Pharmaceutical (CSMYF) Overvalued in 2026?
Based on GuruFocus' analysis, COSMOS Pharmaceutical stock appears to be undervalued.
The current stock price of $37.06 is trading 23.8% below its estimated GF Value™ of $48.62.
Key valuation signals for CSMYF:
Cash-to-Debt: 0.61 (58% below median its 10-year median of 1.45)
GF Value™: $48.62 vs. price of $37.06 (23.8% below fair value)
Industry Position: 22.8% below the Healthcare Providers & Services median (#337 of 669)
No single metric tells the full story. See the CSMYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company emphasizes convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company's revenue is derived from common grocery sales. It also operates a private grocery brand called ON 365.
87GF Score
Get the complete analysis for CSMYF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSMYF has been successfully added to your 
